Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
CNS Drugs
Published in: CNS Drugs 11/2005

01-11-2005 | Leading Article

The Role of Alpha-4 Integrin in the Aetiology of Multiple Sclerosis

Current Knowledge and Therapeutic Implications

Authors: Dr William A. Sheremata, Alireza Minagar, J. Steven Alexander, Timothy Vollmer

Published in: CNS Drugs | Issue 11/2005

Login to get access

Abstract

Multiple sclerosis (MS) has been recognised as a disease since the mid-19th century. The delineation of its CNS pathology, revealing the presence of inflammatory demyelination and relative sparing of axons, was originally interpreted as evidence of infection. Despite many studies, a primary infectious aetiology of MS has not been found. However, the occurrence of acute demyelinating disease following a variety of infections and vaccinations, leading to MS in about a third of cases, provides evidence for the existence of an auto-allergic pathogenesis for the disease.
Improved understanding of the role of the blood-brain barrier in protecting the CNS, and the mechanisms by which cells gain entry into the brain and spinal cord has advanced the understanding of MS. Evidence of the central role of the adhesion molecule α4β1-integrin (very late activation antigen-4 [VLA-4]) for lymphocytes in endothelial transmigration into the CNS specifically, has provided a major insight into the pathogenesis of human demyelinating disease and its experimental model, experimental autoimmune encephalomyelitis (EAE). This finding has led to a new window of therapeutic opportunity in MS.
Monoclonal antibodies to VLA-4 abrogate the development of EAE in sensitised animals and may actually reverse its clinical and pathological findings in manifest disease. Natalizumab, one such monoclonal antibody, which is administered intravenously, has been found to be a promising agent in the treatment of MS. Although single doses produced no improvement in the speed or quality of recovery from acute exacerbations of MS in a phase II trial, long-term administration (in phase II and phase III trials) have produced significant benefits with results showing both a marked reduction in the risk of new magnetic resonance imaging lesions and a significant reduction in the risk of exacerbations within 2 months of the initiation of therapy. Phase III double-blinded controlled trials have provided additional evidence of safety and a favourable impact on exacerbation rates over the 1 year of administration. Unfortunately, the success of natalizumab has been curtailed by three cases of progressive multifocal leukoencephalopathy, which have prompted the manufacturer to voluntary withdraw the drug from the market. An independent review board is currently investigating the safety of the drug to determine whether it should return to the market.
The demonstration that selective modulation (blocking) of the adhesion molecule VLA-4 by natalizumab in MS, resembling that observed in experimental disease, represents a major advance in rational therapy.
Footnotes
1
Antegren® is the former trade name for natalizumab. The new trade name is Tysabri®. The use of trade names is for product identification purposes only and does not imply endorsement.
 
Literature
1.
Charcot JM. Histologie de la sclerose en plaques. Gaz Hop Paris 1868; 41: 554–66
2.
Compston A, Ebers G, Lassman H, et al. McAlpine’s Multiple Sclerosis. 3rd ed. London: Churchill Livingstone, 1988
3.
Oppenheimer DR. Demyelinating diseases. In: Blackwood W, Corsellis JAN, editors. Greenfield’s neuropathology. 3rd ed. London: Edward Arnold, 1976: 470–499
4.
Noseworthy JH, Lucchinetti C, Rodriguez M, et al. Multiple sclerosis. N Engl J Med 2000; 343: 938–52PubMedCrossRef
5.
Patterson PY. Transfer of allergic encephalomyelitis in rats by means of lymph node cells. J Exp Med 1960; 111: 119–36CrossRef
6.
Bornstein MB, Appel SH. Application of tissue culture to the study of experimental allergic encephalomyelitis: 1. Patterns of demyelination. J Neuropathol Exp Neurol 1961; 20: 141–57CrossRef
7.
Bornstein MB, Raine CS. Multiple sclerosis and experimental allergic encephalomyelitis: specific demyelination of CNS in culture. Neuropathol Appl Neurobiol 1977; 3: 359–67CrossRef
8.
Ben-Nun A, Cohen IR. Genetic control of experimental autoimmune encephalomyelitis at the level of cytotoxic lymphocytes in guinea pigs. Eur J Immunol 1982; 12: 709–13PubMedCrossRef
9.
Behan PO, Kies MW, Lisak RP, et al. In vitro studies: mechanisms of demyelination in experimental allergic encephalitis in non-human primates. Arch Neurol 1973; 29: 4–9PubMedCrossRef
10.
Owens T, Sriram S. The immunology of multiple sclerosis and its animal model experimental allergic encephalomyelitis. Neurol Clin 1995; 13(1): 57–73
11.
12.
Minagar A, Alexander JS. Blood-brain barrier disruption in multiple sclerosis. Mult Scler 2003; 9: 540–9PubMedCrossRef
13.
Yednock TA, Cannon C, Fritz LC, et al. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 1992; 356: 63–6PubMedCrossRef
14.
Carlos TM, Harlan JM. Leukocyte-endothelial adhesion molecules. Blood 1994; 84: 2068–101PubMed
15.
16.
Frenette PS, Wagner DD. Adhesion molecules: Part II: blood vessels and blood cells. N Engl J Med 1996; 335: 43–5PubMedCrossRef
17.
Hickey WF, Hsu BL, Kimura H. T-lymphocyte entry into the central nervous system. J Neurosci Res 1991; 28: 254–60PubMedCrossRef
18.
Engelhardt B, Vestweber D, Hallmann R, et al. E- and P-selectin are not involved in the recruitment of inflammatory cells across the blood-brain barrier in experimental autoimmune encephalomyelitis. Blood 1997; 90: 4459–72PubMed
19.
Carrithers MD, Visintin I, Kang SJ, et al. Differential adhesion molecule requirements for immune surveillance and inflammatory recruitment. Brain 2000; 123: 1092–101PubMedCrossRef
20.
von Andrian UH, MacKay CR. T-cell function and migration: two sides of the same coin. N Engl J Med 2000; 343: 1020–34CrossRef
21.
Vajkoczy P, Laschinger M, Engelhardt B. Alpha4-integrin-VCAM-1 binding mediates G protein-independent capture of encephalitogenic T cell blasts to CNS white matter microves-sels. J Clin Invest 2001; 108: 557–65PubMed
22.
Kerfoot SM, Kubes P. Overlapping roles of P-selectin and alpha 4 integrin to recruit leukocytes to the central nervous system in experimental autoimmune encephalomyelitis. J Immunol 2002; 169: 1000–6PubMed
23.
James WG, Bullard DC, Hickey MJ. Critical role of the alpha 4 integrin/VCAM-1 pathway in cerebral leukocyte trafficking in lupus-prone MRL/fas(lpr) mice. J Immunol 2003; 170: 520–7PubMed
24.
Hogg N, Laschinger M, Giles K, et al. T-cell integrins: more than just sticking points. J Cell Sci 2003; 116 (Pt 23): 4695–705PubMedCrossRef
25.
von Adrian UH, Engelhardt B. α4 integrins as therapeutic targets in autoimmune disease. N Engl J Med 2004; 348: 68–72CrossRef
26.
Birner U, Issekutz TB, Walter U, et al. The role of alpha (4) and LFA-1 integrins in selectin-independent monocyte and neutro-phil migration to joints of rats with adjuvant arthritis. Int Immunol 2000; 12: 141–50PubMedCrossRef
27.
Schwartz S, Mohr A, Knauth M, et al. Acute disseminated encephalomyelitis: a follow-up study of 40 adult patients. Neurology 2001; 56: 1312–8
28.
Hartung HP, Grossman RI. ADEM. Distinct disease or part of the MS spectrum? Neurology 2001; 56: 1257–60PubMed
29.
Murthy JM, Yangala R, Meena AK, et al. Acute disseminated encephalomyelitis: clinical and MRI study from South India. J Neurol Sci 1999; 165: 133–6PubMedCrossRef
30.
Rocklin RE, Sheremata WA, Feldman RG, et al. The Guillain-Barre syndrome and multiple sclerosis: in vitro cellular responses. N Engl J Med 1971; 284: 803–8PubMedCrossRef
31.
Sheremata WA, Cosgrove JBR, Eylar EH. Cellular hypersensitivity to basic myelin (A1) protein and clinical multiple sclerosis. N Engl J Med 1974; 291: 14–7PubMedCrossRef
32.
Hohlfeld R, Meinl E, Weber F, et al. The role of autoimmune T lymphocytes in the pathogenesis of multiple sclerosis. Neurology 1995; 45Suppl. 6: S33–8PubMedCrossRef
33.
Lassmann H, Vass K. Are current immunological concepts of multiple sclerosis reflected by the Immunopathology of its lesions? Springer Semin Immunopathol 1995; 17: 77–87PubMedCrossRef
34.
Lassman H, Raine CS, Antel J, et al. Immunopathology of multiple sclerosis: report on an international meeting held at the Institute of Neurology of the University of Vienna. J Neuroimmunol 1998; 86: 213–7CrossRef
35.
Luccinetti C, Brueck W. Paris J, et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000; 47: 707–17CrossRef
36.
Massacesi L, Genain CP, Lee-Parritz D, et al. Active and passively induced experimental autoimmune encephalomyelitis in common marmosets: as new model for multiple sclerosis. Ann Neurol 1995; 37: 519–30PubMedCrossRef
37.
Uccelli A, Giunti D, Capello E, et al. EAE in the common marmoset Callithrix jacchus. Int MS J 2003; 10: 6–12PubMed
38.
Berger T, Rubner P, Schautzer F, et al. Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med 2004; 349: 139–45CrossRef
39.
Bronstein JM, Lallone RL, Seitz RS, et al. A humoral response to oligodendrocyte-specific protein in MS: a potential molecular mimic. Neurology 1999; 53: 154–61PubMedCrossRef
40.
Vu T, Myers LW, Ellison GW, et al. T-cell responses to oligodendrocyte-specific protein in multiple sclerosis. J Neurosci Res 2001; 66: 506–9PubMedCrossRef
41.
Lang HLE, Jacobsen JL, Ikemizu S, et al. A functional and structural basis for TCR cross-reactivity in multiple sclerosis. Nat Immunol 2002; 3: 940–3PubMedCrossRef
42.
43.
Etzioni A, Doerschuk CM, Harlan JM. Of man and mouse: leukocyte and endothelial adhesion molecule deficiencies. Blood 1999; 94: 3281–8PubMed
44.
Vestweber D, Blanks JE. Mechanisms that regulate the function of the selectins and their ligands. Physiol Rev 1999; 79: 181–213PubMed
45.
Clark EA, Brugge JS. Integrins and signal transduction pathways: the road taken. Science 1995; 268: 233–9PubMedCrossRef
46.
Takada Y, Elices MJ, Crouse C, et al. The primary structure of the alpha 4 subunit of VLA-4: homology to other integrins and a possible cell-cell adhesion function. EMBO J 1989; 8: 1361–8PubMed
47.
48.
Hynes RO. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 1992; 69: 11–25PubMedCrossRef
49.
50.
Kent S, Karlik SJ, Cannon C, et al. A monoclonal antibody to α4 integrin suppresses and reverses active experimental allergic encephalomyelitis. J Neuroimmunol 1995; 58: 1–10PubMedCrossRef
51.
Keszthelyi E, Karlik S, Hyduk S, et al. Evidence for a prolonged role of alpha-4 integrin throughout active experimental allergic encephalomyelitis. Neurology 1996; 47: 1053–9PubMedCrossRef
52.
Hemmerich S, Rosen SD. Carbohydrate sulfotransferases in lymphocyte homing. Glycobiology 2000; 10: 849–56PubMedCrossRef
53.
Sperandio M, Forlow SB, Thatte J, et al. Differential requirements for core2 glucosaminyltransferase for endothelial L-selectin ligand function in vivo. J Immunol 2001; 167: 2268–74PubMed
54.
Ferrell JC, Lipowsky HH. Leukocyte margination and deformation in mesenteric venules of rat. Am J Physiol 1989; 256 (Pt 2): 1667–74
55.
Minagar A, Jy W, Jimenez JJ, et al. Elevated plasma endothelial microparticles in multiple sclerosis. Neurology 2001; 56: 1319–24PubMedCrossRef
56.
Tubridy N, Behan PO, Capildo R, et al. The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group. Neurology 1999; 53(3): 466–72PubMedCrossRef
57.
Minagar A, Sheremata WA, Hume A, et al. Reduction of relapses in multiple sclerosis after Natalizumab (Antegren) treatment. Int MS J (On line) 2000 Mar 15
58.
O’Connor PW, Goodman A, Willmer-Hulme AJ, et al., and the Natalizumab Multiple Sclerosis Trial Group. Randomized multicenter trial of intravenous natalizumab in acute MS relapses: clinical and MRI effects. Neurology 2004; 62: 2038–43PubMedCrossRef
59.
Miller MA, Khan OA, Sheremata WA, et al., and the International Natalizumab MS Trial Group. A controlled trial of natalizumab for relapsing-remitting multiple sclerosis. N Engl J Med 2003; 348: 15–23PubMedCrossRef
60.
Polman C, O’Connor P, Havradova E, et al., for the AFFIRM Investigators. Clinical results from AFFIRM, a randomized, double-blind, placebo controlled, multicenter trial to determine the efficacy and safety of natalizumab in patients with relapsing multiple sclerosis (MS) [abstract]. Neurology 2005; 64(Suppl.1): 146
61.
O’Connor P, Havradova E, Hutchinsdon M, et al., for the AFFIRM Investigators. Safety, tolerability and Immunogenicity of natalizumab: results from the AFFIRM Trial [abstract]. Neurology 2005; 64(Suppl. 1): 146
62.
Miller D, O’Connor P, Havradova E, et al., for the AFFIRM Investigators. The efficacy of natalizumab on magnetic resonance imaging (MRI) measures in patients with relapsing multiple sclerosis (MS): results from the AFFIRM trial. Neurology 2005; 64(Suppl.1) 147
63.
Lin K, Ateeq HS, Hsiung SH, et al. Selective tight binding inhibitors of integrin α4β1 that inhibit allergic airway responses. J Med Chem 1999; 42: 920–34PubMedCrossRef
64.
Kelly TA, Jeanfavre DD, McNeil DW, et al. Cutting edge: a small molecule antagonist of LFA-1 mediated cell adhesion. J Immunol 1999; 163: 5173–7PubMed
65.
Cannella B, Gaupp S, Tilton RG, et al. Differential efficacy of a synthetic antagonist of VLA-4 during the course of chronic relapsing experimental autoimmune encephalomyelitis. J Neurosci Res 2003; 71: 407–16PubMedCrossRef
66.
You TJ, Maxwell DS, Kogan TP, et al. A 3D structure model of integrin alpha 4 beta 1 complex: I. construction of a homology model of beta 1 and ligand binding analysis. Biophys J 2002; 82 (Pt 1): 447–57PubMedCrossRef
67.
Vanderslice P, Biediger RJ, Woodside DG, et al. Development of cell adhesion molecule antagonists as therapeutics for asthma and COPD. Pulm Pharmacol Ther 2004; 17: 1–10PubMedCrossRef
68.
Elices MJ, Osborn L, Takada Y, et al. VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/fibronectin binding site. Cell 1990; 60: 577–84PubMedCrossRef
69.
Dasgupta S, Jana M, Liu X, et al. Myelin basic protein-primed T cells induce nitric oxide synthase in microglial cells. Implications for multiple sclerosis. J Biol Chem 2002; 277(42): 39327–33
70.
Dasgupta S, Jana M, Liu X, et al. Role of very-late antigen-4 (VLA-4) in myelin basic protein-primed T cell contact-induced expression of proinflammatory cytokines in microglial cells. J Biol Chem 2003; 278(25): 22424–31PubMedCrossRef
71.
Calabresi PA, Pelfrey CM, Tranquill LR, et al. VLA-4 expression on peripheral blood lymphocytes is downregulated after treatment of multiple sclerosis with interferon beta. Neurology 1997; 49: 1111–6PubMedCrossRef
72.
Muraro PA, Leist T, Bielekova B, et al. VLA-4/CD49d downregulated on primed T lymphocytes during interferon-beta therapy in multiple sclerosis. J Neuroimmunol 2000; 111: 186–94PubMedCrossRef
73.
Stuve O, Dooley NP, Uhm JH, et al. Interferon beta-1b decreases the migration of T lymphocytes in vitro: effect on matrix metllaoproteinase-9. Ann Neurol 1996; 40: 853–63PubMedCrossRef
74.
Elovaara I, Ukkonen M, Leppakynnas M, et al. Adhesion molecules in multiple sclerosis: relation to subtypes of disease and methylprednisolone therapy. Arch Neurol 2000; 47: 546–51CrossRef
75.
Gelati M, Corsini E, de Rossi M, et al. Methylprednisolone acts on peripheral blood mononuclear cells and endothelium in inhibiting migration phenomena in patients with multiple sclerosis. Arch Neurol 2002; 59: 774–80PubMedCrossRef
76.
Sheremata WA, Vollmer TL, Stone LA, et al. A pharmacokinetic study of intravenous natalizumab in patients with multiple sclerosis. Neurology 1999; 52: 1072–4PubMedCrossRef
77.
78.
Rudick R, Stuart W, Calabresi P, et al. SENTINEL: A randomized, placebo-controlled, Multicenter trial to determine the efficacy and safety of natalizumab, when added to intramuscular interferon beta-1a, in patients with relapsing multiple sclerosis (MS): one-year clinical and MRI results [abstract]. Neurology 2005; 64Suppl. 1: 277
79.
Langer-Gould A, Atlas SW, Bollen AW, et al. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005; 353: 375–81PubMedCrossRef
80.
Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005; 353: 369–74PubMedCrossRef
81.
Van Assche G, Van Ranst J, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s disease. N Engl J Med 2005; 353: 362–8PubMedCrossRef
82.
Berger JR, Koralnik IJ. Editorial. Progressive multifocal leukoencephalopathy and natalizumab: unforeseen consequences. N Engl J Med 2005; 353: 414–6
83.
Jy W, Delgado S, Minagar A, et al. Interferonbeta-1a reduces plasma CD31+ endotheoial microparticles in MS [abstract]. Ann Neurol 2003; 54Suppl. 7: S60
84.
The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: 1. clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 655–61CrossRef
85.
Paty DW, Li KDB, the UBC MS/MRI Group and the IFN Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. Neurology 1993; 42: 662–7CrossRef
86.
Stone LA, Frank JA, Albert PS, et al. Characterization of MRI response to treatment with interferon beta-1b: contrast-enhancing MRI lesion frequency as a primary outcome measure. Neurology 1997 Sep; 49: 862–9PubMedCrossRef
87.
Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996; 39: 285–94PubMedCrossRef
88.
PRISMS (Prevention of Relapses and Disability by Interferon β-1a subacutaneously in multiple sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet 2002; 352: 1498–504
89.
The PRISMS Study Group and the University of British Columbia MS/MRI Analysis Group. PRISMS-4: longer term efficacy of interferon-beta-1a in relapsing MS. Neurology 2001; 56: 1628–36CrossRef
90.
Panitch H, Goodin DS, Francis G, et al. Randomized, comparative study of interferon β-1a treatment regimens in MS: The EVIDENCE Trial. Neurology 2002; 59: 1496–506PubMedCrossRef
91.
Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 1995; 45: 1268–76PubMedCrossRef
92.
93.
94.
Ghosh S, Goldin E, Gordon FH, et al., Natalizumab Pan-European Study Group. Natalizumab for active Crohn’s disease. N Engl J Med 2003; 348: 24–32PubMedCrossRef
Metadata
Title
The Role of Alpha-4 Integrin in the Aetiology of Multiple Sclerosis
Current Knowledge and Therapeutic Implications
Authors
Dr William A. Sheremata
Alireza Minagar
J. Steven Alexander
Timothy Vollmer
Publication date
01-11-2005
Publisher
Springer International Publishing
Published in
CNS Drugs / Issue 11/2005
Print ISSN: 1172-7047
Electronic ISSN: 1179-1934
DOI
https://doi.org/10.2165/00023210-200519110-00002

Other articles of this Issue 11/2005

CNS Drugs 11/2005 Go to the issue

Review Article

Advances in Drug Treatments for Children and Adolescents with Autism and Other Pervasive Developmental Disorders

Review Article

The Use of Triptans in the Management of Menstrual Migraine

Current Opinion

Overtreatment in Epilepsy

Review Article

Head-To-Head Comparison of the Costs of Atypical Antipsychotics

Adis Drug Profile

Rotigotine

Adis Drug Profile

Rotigotine